JIN-A02

JIN-A02 is a novel, orally administered, fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by J INTS BIO. It is designed to selectively and reversibly inhibit EGFR mutations, specifically targeting the C797S and T790M mutations that frequently drive resistance to third-generation EGFR-TKIs like osimertinib. JIN-A02 exhibits high selectivity for mutant EGFR over wild-type EGFR, potentially reducing off-target toxicities. Preclinical and early clinical data indicate that the compound can penetrate the blood-brain barrier, showing activity against intracranial metastases. It is currently being evaluated in Phase 1/2 clinical trials for patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on prior EGFR-TKI therapies.